Zobrazeno 1 - 10
of 555
pro vyhledávání: '"C3 Glomerulonephritis"'
Autor:
Athena Y. Gong, Ying Jin Qiao, Mengxuan Chen, Zubia Alam, Deepak K. Malhotra, Lance Dworkin, Wenjun Ju, William T. Gunning
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Ethyl carbamate (EC) is a process contaminant found in fermented foods and alcoholic beverages. Metabolic conversion of ethyl carbamate generates vinyl carbamate (VC), a carcinogenic metabolite. EC, as a Group 2A probable human carcinogen, and the mo
Externí odkaz:
https://doaj.org/article/94398cde3f994f248dc86b431cc97144
Publikováno v:
BMC Nephrology, Vol 24, Iss 1, Pp 1-6 (2023)
Abstract Background Immune checkpoint inhibitors (ICIs) are increasingly being used in the treatment of several cancers. Pembrolizumab is an anti-programmed cell death-1 (anti-PD-1) monoclonal antibody that is approved for the treatment of metastatic
Externí odkaz:
https://doaj.org/article/db339355101349f3bb18246660749a32
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
Dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) are types of membranoproliferative glomerulonephritis classified as C3 glomerulopathies. These conditions are characterized by an increased number of intraglomerular cells and diffuse thick
Externí odkaz:
https://doaj.org/article/b06c6593ed4d45b482db078caa7cadb5
Autor:
Thomas Welte, Frederic Arnold, Lukas Westermann, Felix A. Rottmann, Martin J. Hug, Elke Neumann-Haefelin, Athina Ganner
Publikováno v:
BMC Nephrology, Vol 24, Iss 1, Pp 1-9 (2023)
Abstract Background C3 Glomerulopathy (C3G) is a rare glomerular disease caused by dysregulation of the complement pathway. Based on its pathophysiology, treatment with the monoclonal antibody eculizumab targeting complement C5 may be a therapeutic o
Externí odkaz:
https://doaj.org/article/d698782c82b94a038f38014bb9e2347d
Publikováno v:
Терапевтический архив, Vol 94, Iss 6, Pp 718-724 (2022)
Aim. To analyze the outcomes of C3-glomerulopathy (C3-GP) and determine the associated factors. Materials and methods. A retrospective single-center study included 60 patients with newly diagnosed C3-GP (with primary C3-GP pC3-GP 82%). Of these, 4
Externí odkaz:
https://doaj.org/article/a00ca1a09ef54a4e834a17888fe69501
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jeong-Hoon Lim, Seong-Won Shin, Mee-Seon Kim, Man-Hoon Han, Yong-Jin Kim, Hee-Yeon Jung, Ji-Young Choi, Jang-Hee Cho, Sun-Hee Park, Yong-Lim Kim, Deokbi Hwang, Woo-Sung Yun, Hyung-Kee Kim, Seung Huh, Eun Sang Yoo, Dong Il Won, Chan-Duck Kim
Publikováno v:
Medicina, Vol 59, Iss 7, p 1308 (2023)
C3 glomerulonephritis (C3GN) is a rare cause of end-stage kidney disease and frequently recurrent in allografts following kidney transplantation (KT). Herein, we describe the case of a kidney transplant recipient who developed recurrent C3GN along wi
Externí odkaz:
https://doaj.org/article/e56e992dcdc949d687229f032568747f
Publikováno v:
Case Reports in Nephrology and Dialysis, Vol 11, Iss 3, Pp 261-269 (2021)
C3 glomerulonephritis (C3GN) is a rare kidney disease resulting from dysregulation of the alternative complement cascade. Without treatment, approximately 70% of affected children and 30–50% of affected adults will develop worsening of proteinuria
Externí odkaz:
https://doaj.org/article/71ddfca6306342f0867479d1642dcd80
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.